Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: Report of two cases and review of the literature

被引:3
作者
Piamsomboon, S
Termrungruanglert, W
Kudelka, AP
Edwards, CL
Freedman, RS
Mountain, CF
Delclos, L
Aapro, MS
DeCaro, L
Bianca, J
Verschraegen, CF
Kavanagh, JJ
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030
[2] MAHIDOL UNIV,SINRAJ HOSP,BANGKOK 10700,THAILAND
[3] CHULALONGKORN UNIV HOSP,BANGKOK,THAILAND
[4] EUROPEAN INST ONCOL,MILAN,ITALY
[5] ST LUKES EPISCOPAL HOSP,HOUSTON,TX 77030
[6] TEXAS HEART INST,HOUSTON,TX 77030
[7] DIAGNOST CLIN LONGVIEW,LONGVIEW,TX 75605
关键词
13-cis-retinoic acid; cervix; interferon-alpha; squamous cell carcinoma;
D O I
10.1097/00001813-199609000-00014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrent and metastatic cervical carcinoma has very poor prognosis, mainly because there is no effective systemic therapy which would increase the duration of survival. Biologic agents have recently been found to have activity in cervical carcinoma, The combination of interferon (IFN)-alpha and 13-cis-retinoic acid has additive and synergistic antitumor activity. Both have antiviral, immunoregulatory and antiangiogenic properties, and are known to modulate malignant cell differentiation and proliferation. We report two patients with recurrent squamous cell carcinoma (SCC) of the cervix who had small-volume progressive metastatic disease, and were treated with a combination of IFN-alpha and 13-cis-retinoic acid, The first patient had pelvic lymph node metastases and the other had rung metastases. The previously progressive diseases remained stable for a prolonged period of time, 3 and 4 years, with a good quality of life. These cases suggest the possibility of using IFN-alpha and 13-cis-retinoic acid as a treatment for small-volume residual disease or as postinduction therapy in patients at high risk for disease recurrence.
引用
收藏
页码:800 / 804
页数:5
相关论文
共 48 条
[1]  
AGARWAL C, 1994, CANCER RES, V54, P2108
[2]  
ALFTHAN O, 1986, INT J IMMUNOL, V11, P5
[3]  
BANDYOPADHYAY SK, 1992, CELL GROWTH DIFFER, V3, P369
[4]  
CASTAIGNE S, 1990, BLOOD, V76, P1704
[5]  
CHAUVERGNE J, 1990, B CANCER, V77, P1007
[6]  
CHEN ZX, 1991, BLOOD, V78, P1413
[7]  
DINNEY PN, 1996, P AM ASSOC CANC RES, V37, P56
[8]   RECOMBINANT HUMAN INTERFERON SENSITIZES RESISTANT MYELOID LEUKEMIC-CELLS TO INDUCTION OF TERMINAL DIFFERENTIATION [J].
GRANT, S ;
BHALLA, K ;
WEINSTEIN, B ;
PESTKA, S ;
MILENO, MD ;
FISHER, PB .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 130 (01) :379-388
[9]   PHASE-II STUDY OF 13-CIS-RETINOIC ACID PLUS INTERFERON-ALPHA(2A) IN HEAVILY PRETREATED SQUAMOUS CARCINOMA OF THE CERVIX [J].
HALLUM, AV ;
ALBERTS, DS ;
LIPPMAN, SM ;
INCLAN, L ;
SHAMDAS, GJ ;
CHILDERS, JM ;
SURWIT, EA ;
MODIANO, M ;
HATCH, KD .
GYNECOLOGIC ONCOLOGY, 1995, 56 (03) :382-386
[10]   A DOMINANT-NEGATIVE MUTANT OF 2-5A-DEPENDENT RNASE SUPPRESSES ANTIPROLIFERATIVE AND ANTIVIRAL EFFECTS OF INTERFERON [J].
HASSEL, BA ;
ZHOU, A ;
SOTOMAYOR, C ;
MARAN, A ;
SILVERMAN, RH .
EMBO JOURNAL, 1993, 12 (08) :3297-3304